Drug Development · us
New Therapy for Chronic Sciatica Receives FDA Fast Track Designation, First-in-Human Trial Evaluates Safety of Epidural Administration
Consano Bio’s platelet-derived multi-protein product C-1101 aims to simultaneously suppress inflammation and promote repair near damaged nerves; however, evidence of efficacy remains limited to the preclinical stage, and the ongoing 24-person trial will first address questions of safety.
Chronic sciatica often radiates from the lower back down the leg, and some patients continue to experience long-term pain despite medication, rehabilitation, or injection therapy. The U.S. Food and Drug Administration (FDA) has now granted Fast Track designation to Consano Bio’s experimental biologic C-1101, accelerating communication with regulators for a therapy designed to directly alter the local environment around nerve damage.
C-1101 is an allogeneic, multi-protein biologic made from human plasma and platelets and is intended to be delivered near the affected nerve through a transforaminal epidural injection. Rather than relying on a single molecule to block pain signals, the development concept uses multiple protein components to modulate inflammation and stimulate cellular repair at the site of injury; however, this mechanism is currently supported mainly by laboratory and animal studies.
Consano Bio said the FDA granted Fast Track designation after evaluating the unmet medical need and a comprehensive nonclinical data package. The decision follows the FDA’s clearance of the company’s Investigational New Drug application in July 2026. However, Fast Track designation is intended to increase interaction with the FDA during development and improve review efficiency; it does not mean that the drug has been approved, nor does it constitute an endorsement of clinical efficacy or safety.
Published preclinical studies show that C-1101 can suppress several pro-inflammatory cytokines in stimulated human monocytes and reduce the activity of certain inflammatory pathways in spine-derived cells. In a mouse model of peripheral neuropathy, both tested doses reduced touch-evoked pain. These findings provide a rationale for proceeding to human studies, but they cannot establish that C-1101 improves patients’ pain, mobility, or quality of life.
The ongoing Phase 1 C-1101-101 trial uses a randomized, double-blind design and is expected to enroll 24 adults with painful lumbosacral radiculopathy who have responded inadequately to conservative treatment. Participants in three sequentially progressing dose cohorts will receive a single transforaminal epidural injection of either C-1101 or sterile saline. The study will primarily track treatment-emergent adverse events and adverse events of special interest over 24 weeks, rather than aiming principally to establish efficacy.
The trial is recruiting in Australia and is planned to expand to the United States. The next key questions extend beyond whether a signal of pain improvement can be observed. They also include batch-to-batch consistency of the allogeneic plasma- and platelet-derived product, the risks of local injection, and how to establish a clear dose-response and mechanism-of-action relationship for its multi-protein components. Whether C-1101 can progress from a biologically compelling concept to a usable therapy will need to be answered by this small safety study and subsequent larger controlled trials.